The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy

Overview of attention for article published in Clinical Cancer Research, December 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

So far, Altmetric has seen 25 tweets from 20 users, with an upper bound of 38,023 followers.

生体内でエピジェネティックなリプログラミングにより疲弊したT細胞を若返らせる次世代免疫療法 https://t.co/ASicx4cI3z ※AACR会員記事ですがめちゃくちゃ面白い

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 21 additional tweets.